Inflammatory disease Archives

News and Trends 8 Sep 2022

Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M

Arcutis Biotherapeutics, Inc. has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately held, preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases. Arcutis BioTherapeutics will acquire the outstanding shares of Ducentis for an upfront cash payment of approximately $16 million and Arcutis stock valued at approximately $14 million, […]

September 8, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 2 Sep 2022

Abivax pulls in €49.2M but needs more to complete ulcerative colitis program

French biotech company Abivax has completed an oversubscribed €49.2 million ($49 million) financing round. This included U.S. and European biotech specialist investors, led by TCGX, with participation from Venrock Healthcare Capital Partners, Deep Track Capital, Sofinnova Partners, Invus, and Truffle Capital through the completion of two transactions. The first was a reserved capital increase of […]

September 2, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Researchers try to bridge gap in link for patients with salmonella infection and clogged arteries

Researchers from Taiwan have discovered that patients with non-typhoidal salmonella (NTS) have higher aortic calcification and elevated plasma levels, which are an inflammatory biomarker. They say their findings suggest the need for early diagnosis of the condition in patients with atherosclerosis risk factors. NTS is a foodborne bacterium causing gastrointestinal infections and can cause life-threatening […]

August 31, 2022 - 4 minutesmins - By Liza Laws

News and Trends 19 Aug 2022

World’s first CAR-T for treatment of inflammatory disorders of the central nervous system approved in China

China’s National Medical Products (NMPA) has approved an investigational new drug application from IASO Bio for the new extended indication of neuromyelitis optica spectrum disorder (NMOSD). Neuromyelitis optica spectrum disorders previously known as Devic disease or neuromyelitis optica are inflammatory disorders of the central nervous system characterized by severe, immune-mediated demyelination and axonal damage predominantly targeting […]

August 19, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Aug 2022

Success across the board for C4X Discovery Holdings plc and its partnerships

Drug discovery company C4X Discovery Holdings plc released a report today (August 2) detailing the continued success of its relationship with partners across its portfolio. The company says it is happy to report it received its first milestone payment last month of €3 million ($3.1 million) from Sanofi under the out-licensing agreement for its IL-17A […]

August 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 18 Jul 2022

Enterome and Nestlé Health Science to work on food allergies and inflammatory bowel disease

Enterome, a clinical stage biopharmaceutical company developing immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, has signed a strategic R&D collaboration and license agreement with Nestlé Health Science targeting food allergies and inflammatory bowel disease (IBD). The collaboration aims to develop and commercialize Enterome’s lead EndoMimics pipeline candidate EB1010. EB1010 is a local […]

July 18, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 Jul 2022

AI being used to perform molecular analysis of biopsies from bowel disease patients

Artificial intelligence will be used to perform molecular analysis of biopsies from unidentified Inflammatory Bowel Disease (IBD) patients in a bid to help those with immune diseases and cancer. Athos Therapeutics, a late-stage preclinical, California-based biotech company uses artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced this week (July 11) […]

July 12, 2022 - 2 minutesmins - By Liza Laws

shutterstock irritable bowel syndrome IBS

News and Trends 23 Jun 2022

Gemelli Biotech to work on gastrointestinal diseases with new $19M funding

U.S.-headquartered Gemelli Biotech Corp, which focuses on precision diagnostics for gastrointestinal (GI) diseases, has completed a $19 million series A finance round. Blue Ox Healthcare Partners, a private equity firm providing growth capital to companies targeting precision health and value-based care, led the investment round, joined by founding investor Cedars-Sinai, along with Carolina Angel Network, […]

June 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Jun 2022

Upstream Bio to target asthma as it launches with $200M financing

Upstream Bio, a U.S. biotech company focused on inflammation, today exited stealth mode with $200M Series A financing. The company said the funding will allow it to advance its lead program UPB-101, a clinical-stage monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor. It added the investment will also help build a pipeline of assets […]

June 2, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 27 May 2022

Up to 500 new jobs as Lilly invests $2.1B in new manufacturing sites

Eli Lilly and Company is boosting its manufacturing footprint by investing $2.1 billion in two new U.S. sites. The new facilities are located at Indiana’s LEAP Lebanon Innovation and Research District in Boone County. David A. Ricks, Lilly’s chair and CEO, said: “These new sites will add capacity in support of our growing pipeline of […]

May 27, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Apr 2022

OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B

The UK firm OMass Therapeutics has unveiled a €90M (£75.5M) Series B financing to bankroll the development of small molecules against so-called ‘undruggable’ targets, including one that sank Quench Bio last year. In 2020, Quench Bio captured the imagination of investors with the US firm’s ambition to develop a new class of anti-inflammatory drugs. The […]

April 28, 2022 - 3 minutesmins - By Jonathan Smith

UK kynos epidarex anti inflammatory drugs

News and Trends 8 Apr 2022

Epidarex Backs UK Startup Developing Emerging Anti-Inflammatory Drugs

The UK-US venture capitalist Epidarex Capital has led an €11M (£9M) funding round raised by the Edinburgh-based Kynos Therapeutics, which aims to develop anti-inflammatory treatments by blocking an emerging metabolic target. Much of the UK’s biotech innovation is concentrated in the so-called Golden Triangle, encompassing the hubs of Cambridge, Oxford, and London. In 2020, Epidarex […]

April 8, 2022 - 3 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us